Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief executive officer as the ...

Immunic has hired Roche veteran Erik Lundgren to succeed co-founder Daniel Vitt as the biotechnology company's new chief executive. Immunic on Wednesday said Lundgren, who most recently served as ...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of distinguished ...

Immunic, Inc IMUX announced it strengthened its leadership team on Wednesday as the company prepares to advance its multiple ...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced financial results for the first quarter ...

One stock that might be an intriguing choice for investors right now is Immunic, Inc. IMUX. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings ...

Immunic, Inc. (NASDAQ:IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million. Immunic reported that the first ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

In our previous article on Immunic (IMUX), we highlighted some of the important insights from the interview hosted by TipRanks with the company’s President and CEO Dr. Daniel Vitt. The CEO shed light ...

NEW YORK, November 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...